Science
In this brief episode we explore key questions such as: 1. What if we could use genetic evolution and modifying the ubiquitin-proteasome pathway for more targeted therapy in proteinopathies, for example utilizing directed evolution and protein engineering with ubiquitin or regions of the proteasome complex, to include antisense mRNA for key motifs apart of amyloid precursor protein (APP), PSEN1 or SNCA? Could we better target the histopathological hallmarks associated with Alzheimer’s disease, such as the plaques of amyloid-beta, that are indicated in Alzheimer’s disease progression?
2. What if we could use different modified tRNA, or agents in the protein translation pathway, to facilitate therapy for NDD proteinopathies.
In reference to question 1, check out this article on the UPS system in the body: The Ubiquitin–Proteasome System in Immune Cells .